

--REFERENCE TO RELATED APPLICATIONS

This application is a divisional application of allowed U.S. Application Serial No. 09/029,535, filed February 27, 1998, which is the National Stage application of international application PCT/GB96/02134 filed August 28, 1996, published as WO 97/07789 on March 6, 1997, and claims priority from British Application 9517622.8 filed August 29, 1995. Reference is made to U.S. Application Serial No. 10/061,044 filed January 30, 2002 as a divisional of U.S. Application Serial No. 09/029,535. Reference is also made to four additional applications, also filed as divisional applications of U.S. Application Serial No. 09/029,535 on February 22, 2002, application numbers to be assigned, (Attorney docket numbers 674543-2001.2, 674543-2001.3, 674543-2001.4 and 674543-2001.6).

The above-mentioned applications, as well as all documents cited herein and documents referenced or cited in documents cited herein, are hereby incorporated herein by reference---

IN THE CLAIMS:

Kindly cancel claims 1-13, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

Kindly add new claims 14-21, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents:

--14. (New) A method for reducing circulating fatty acids from, or maintained by, reductase activity of 11-Beta-hydroxysteroid dehydrogenase 1 (11-Beta HSD1) in adipose tissue in a patient in need thereof comprising inhibiting said reductase activity of 11-Beta HSD1 in adipose tissue in said patient.

15. (New) A method for reducing circulating fatty acids from, or maintained by, reductase activity of 11-Beta-hydroxysteroid dehydrogenase 1 (11-Beta HSD1) in adipose tissue in a patient in need thereof comprising administering to said patient an inhibitor of said reductase activity of 11-Beta HSD1 in adipose tissue, in an amount effective to so inhibit said reductase activity of 11-Beta HSD1 in adipose tissue.

16. (New) The method of claim 14 wherein the inhibiting is by administering carbenoxolone or a pharmaceutically acceptable salt thereof.

17. (New) The method of claim 15 wherein the inhibitor is carbenoxolone or a pharmaceutically acceptable salt thereof.

18. (New) The method of claim 14, wherein said patient suffers from one of the following: obesity, insulin resistance, or obesity and insulin resistance.

19. (New) The method of claim 15, wherein said patient suffers from one of the following: obesity, insulin resistance, or obesity and insulin resistance.

20. (New) A method for treating obesity, insulin resistance, or obesity and insulin resistance by regulating reductase activity of 11-Beta-hydroxysteroid dehydrogenase 1 (11-Beta HSD1) in adipose tissue in a patient in need thereof comprising inhibiting said reductase activity of 11-Beta HSD1 in adipose tissue in said patient.

21. (New) A method for treating obesity, insulin resistance, or obesity and insulin resistance by regulating reductase activity of 11-Beta-hydroxysteroid dehydrogenase 1 (11-Beta HSD1) in adipose tissue in a patient in need thereof comprising administering to said patient an inhibitor of said reductase activity of 11-Beta HSD1 in adipose tissue, in an amount effective to so inhibit said reductase activity of 11-Beta HSD1 in adipose tissue.--

**IN THE ABSTRACT:**

Please accept the enclosed page entitled "Abstract".

SEARCHED  
INDEXED  
SERIALIZED  
FILED